Radiopharmaceuticals

Nuclear Imaging Equipment Market worth $4.6 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Montag, Februar 22, 2021
Medical physics, Medicine, Nuclear medicine, Neuroimaging, Applied sciences, Medicinal radiochemistry, Radiobiology, Radiopharmaceuticals, Single-photon emission computed tomography, Siemens Healthineers, GE Healthcare, Positron emission tomography

Based on product, the market is segmented into hybrid PET imaging systems, SPECT imaging systems, and planar scintigraphy imaging systems.

Key Points: 
  • Based on product, the market is segmented into hybrid PET imaging systems, SPECT imaging systems, and planar scintigraphy imaging systems.
  • The SPECT imaging systems segment is further categorized into standalone and hybrid imaging systems.
  • Hospitals accounted for the largest share of the global nuclear imaging equipment market in 2019.
  • The prominent players in the global nuclear imaging equipment market include are Siemens Healthineers (Germany), Philips Healthcare (Netherlands), and GE Healthcare (US).

Nuclear Imaging Equipment Market worth $4.6 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Montag, Februar 22, 2021
Medical physics, Medicine, Nuclear medicine, Neuroimaging, Applied sciences, Medicinal radiochemistry, Radiobiology, Radiopharmaceuticals, Single-photon emission computed tomography, Siemens Healthineers, GE Healthcare, Positron emission tomography

Based on product, the market is segmented into hybrid PET imaging systems, SPECT imaging systems, and planar scintigraphy imaging systems.

Key Points: 
  • Based on product, the market is segmented into hybrid PET imaging systems, SPECT imaging systems, and planar scintigraphy imaging systems.
  • The SPECT imaging systems segment is further categorized into standalone and hybrid imaging systems.
  • Hospitals accounted for the largest share of the global nuclear imaging equipment market in 2019.
  • The prominent players in the global nuclear imaging equipment market include are Siemens Healthineers (Germany), Philips Healthcare (Netherlands), and GE Healthcare (US).

Surgical Imaging Market worth $2.4 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Freitag, Februar 12, 2021
Companies, Manufacturing, Secondary sector of the economy, Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, Philips, Siemens, Marketplace

The Surgical Imaging Market includes Tier I and II vendors GE Healthcare (UK), Siemens AG (Germany), Koninklijke Philips (Netherlands), and Ziehm Imaging (Germany) among others.

Key Points: 
  • The Surgical Imaging Market includes Tier I and II vendors GE Healthcare (UK), Siemens AG (Germany), Koninklijke Philips (Netherlands), and Ziehm Imaging (Germany) among others.
  • The companies have a large market spread across various countries in North America, Europe, Asia Pacific, and the Rest of the World.
  • Based on technology, the Surgical Imaging Market has been segmented into image intensifier C-arms and FPD C-arms.
  • Geographically, the Surgical Imaging Market is segmented into North America, Europe, Asia Pacific (APAC), and the Rest of the World.

Surgical Imaging Market worth $2.4 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Freitag, Februar 12, 2021
Companies, Manufacturing, Secondary sector of the economy, Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, Philips, Siemens, Marketplace

The Surgical Imaging Market includes Tier I and II vendors GE Healthcare (UK), Siemens AG (Germany), Koninklijke Philips (Netherlands), and Ziehm Imaging (Germany) among others.

Key Points: 
  • The Surgical Imaging Market includes Tier I and II vendors GE Healthcare (UK), Siemens AG (Germany), Koninklijke Philips (Netherlands), and Ziehm Imaging (Germany) among others.
  • The companies have a large market spread across various countries in North America, Europe, Asia Pacific, and the Rest of the World.
  • Based on technology, the Surgical Imaging Market has been segmented into image intensifier C-arms and FPD C-arms.
  • Geographically, the Surgical Imaging Market is segmented into North America, Europe, Asia Pacific (APAC), and the Rest of the World.

Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting

Retrieved on: 
Donnerstag, Februar 4, 2021
FDA, Genetics, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Oncology, Anatomy, Branches of biology, Medicine, Radiopharmaceuticals, Histopathology, Prostate cancer, Billerica, Massachusetts, Prostate

Two of the abstracts relate to PyL, the Companys PET/CT imaging agent for prostate cancer, and the third abstract relates to 1095, the Companys radiopharmaceutical therapeutic for metastatic castration resistant prostate cancer.

Key Points: 
  • Two of the abstracts relate to PyL, the Companys PET/CT imaging agent for prostate cancer, and the third abstract relates to 1095, the Companys radiopharmaceutical therapeutic for metastatic castration resistant prostate cancer.
  • The presentations will be made available for the duration of conference.
  • Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products.
  • The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada, and Sweden.

GE Healthcare Named "2020 Global Company of the Year" by Frost & Sullivan for its AI-based Command Centers that Help Hospitals Make Real-time Decisions That Improve Care Delivery

Retrieved on: 
Montag, Februar 1, 2021
Companies, Economy of the United States, Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, General Electric

SANTA CLARA, Calif., Feb. 1, 2021 /PRNewswire/ -- Based on its recent analysis of the global healthcare command center market, Frost & Sullivan recognizes GE Healthcare with the 2020 Global Company of the Year Award.

Key Points: 
  • SANTA CLARA, Calif., Feb. 1, 2021 /PRNewswire/ -- Based on its recent analysis of the global healthcare command center market, Frost & Sullivan recognizes GE Healthcare with the 2020 Global Company of the Year Award.
  • GE Healthcare enables customers to develop virtual or physical command centers that support single departments, hospitals, health systems, and even states or regions.
  • It offers a variety of partnership roles and pricing models to expand access to its exceptional services," said Siddharth Shah, Program Manager at Frost & Sullivan."
  • Over 11 physical command centers, 210 hospitals with the command center software, spread over 6 countries are experiencing the benefits of GE's solution that encompasses about 30 real-time apps or 'Tiles'."

GE Healthcare Named "2020 Global Company of the Year" by Frost & Sullivan for its AI-based Command Centers that Help Hospitals Make Real-time Decisions That Improve Care Delivery

Retrieved on: 
Montag, Februar 1, 2021
Companies, Economy of the United States, Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, General Electric

SANTA CLARA, Calif., Feb. 1, 2021 /PRNewswire/ -- Based on its recent analysis of the global healthcare command center market, Frost & Sullivan recognizes GE Healthcare with the 2020 Global Company of the Year Award.

Key Points: 
  • SANTA CLARA, Calif., Feb. 1, 2021 /PRNewswire/ -- Based on its recent analysis of the global healthcare command center market, Frost & Sullivan recognizes GE Healthcare with the 2020 Global Company of the Year Award.
  • GE Healthcare enables customers to develop virtual or physical command centers that support single departments, hospitals, health systems, and even states or regions.
  • It offers a variety of partnership roles and pricing models to expand access to its exceptional services," said Siddharth Shah, Program Manager at Frost & Sullivan."
  • Over 11 physical command centers, 210 hospitals with the command center software, spread over 6 countries are experiencing the benefits of GE's solution that encompasses about 30 real-time apps or 'Tiles'."

Q BioMed Expands Strontium89 Reach Through Agreement with UroGPO, the Largest Group Purchasing Organization for Independent Urology Clinics in the US

Retrieved on: 
Montag, Februar 1, 2021
Musculoskeletal system, Chemistry, Physical sciences, Alkaline earth metals, Chemical elements, Radiopharmaceuticals, Strontium-89, Strontium, Bone, Urology, Radium, Prostate cancer

Strontium89 will be offered to UroGPO urology offices that treat patients with painful bone metastases from prostate and other urological cancers.

Key Points: 
  • Strontium89 will be offered to UroGPO urology offices that treat patients with painful bone metastases from prostate and other urological cancers.
  • We are confident that this will enable us to engage with new customers throughout the U.S. and see increased use of Strontium89 ," stated Q BioMed CEO Denis Corin.
  • Bone marrow toxicity is to be expected following the administration of Strontium-89 Chloride Injection, particularly white blood cells and platelets.
  • Because Strontium-89 Chloride Injection acts as a calcium analog, secretion of Strontium-89 Chloride Injection into human milk is likely.

Fuzionaire Radioisotope Technologies K.K. and Nihon Medi-Physics Enter Feasibility Study Agreement

Retrieved on: 
Dienstag, Januar 26, 2021
Health, Medical devices, Radiology, Research, Science, Pharmaceutical, Biotechnology, Medicine, Physical sciences, Medicinal radiochemistry, Nuclear medicine, Medical physics, Radiopharmaceuticals, Neuroimaging, Radioactivity, Positron Corporation, Positron emission tomography, Positron emission

(FRIT) today announced that it has entered into a feasibility study agreement with Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan, engaged in R&D, manufacturing, and distribution.

Key Points: 
  • (FRIT) today announced that it has entered into a feasibility study agreement with Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan, engaged in R&D, manufacturing, and distribution.
  • Founded in 2019, FRIT is a joint venture between radiopharmaceutical companies Fuzionaire Diagnostics, Inc. (Fuzionaire Dx) and Japan Medical Isotope Technology Development K.K.
  • Under the agreement, NMP will evaluate the ability of Fuzionaire Dxs technology to create a new class of positron emission tomography (PET) radiopharmaceuticals.
  • Fuzionaire Diagnostics (Fuzionaire Dx) is a nuclear medicine company on a mission to improve disease, diagnosis, and treatment.

RadioMedix & Curium Announce Permanent HCPCS Code for DetectnetTM (copper Cu 64 dotatate injection)

Retrieved on: 
Dienstag, Januar 26, 2021
Orphan drugs, Radiopharmaceuticals, Branches of biology, Drugs, Medicine, G protein-coupled receptors, Chelating agents, Macrocycles, DOTA-TATE, Somatostatin receptor 2, Copper (64Cu) oxodotreotide, Somatostatin

Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.

Key Points: 
  • Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.
  • The uptake of copper Cu 64 dotatate reflects the level of somatostatin receptor density in NETs, however, uptake can also be seen in a variety of other tumors that also express somatostatin receptors.
  • A negative scan after the administration of Detectnet in patients who do not have a history of NET disease does not rule out disease.
  • Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).